Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Site-Specific Differences of Eligibility for Adjuvant Immunotherapy Among Urothelial Carcinoma Patients Treated With Radical Surgery: Results From a Multicenter Cohort Study.
Narita C, Urabe F, Fukuokaya W, Iwatani K, Imai Y, Yasue K, Mori K, Aikawa K, Yanagisawa T, Kimura S, Tashiro K, Tsuzuki S, Yamada Y, Yuen SKK, Teoh JY, Shimomura T, Yamada H, Furuta A, Miki J, Kimura T; JIKEI-YAYOI Collaborative Group. Narita C, et al. Among authors: yasue k. Clin Genitourin Cancer. 2024 Mar 21:102082. doi: 10.1016/j.clgc.2024.102082. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 38641443
How long is long enough to secure disease control after low-dose-rate brachytherapy in combination with other modalities in intermediate-risk, localized prostate cancer?
Urabe F, Kimura T, Sasaki H, Tashiro K, Iwatani K, Yasue K, Aoki M, Sato S, Takahashi H, Miki K, Egawa S. Urabe F, et al. Among authors: yasue k. Int J Clin Oncol. 2022 Jan;27(1):184-193. doi: 10.1007/s10147-021-02040-5. Epub 2021 Oct 2. Int J Clin Oncol. 2022. PMID: 34599724 Clinical Trial.
Clinical characteristics of secondary bladder cancer developing after low-/high-dose-rate brachytherapy to treat localized prostate cancer.
Miyajima K, Suzuki H, Urabe F, Iwatani K, Imai Y, Yasue K, Yanagisawa T, Kimura S, Tashiro K, Tsuzuki S, Koike Y, Miki J, Yuen S, Sasaki T, Aoki M, Sato S, Takahashi H, Miki K, Kimura T. Miyajima K, et al. Among authors: yasue k. Int J Clin Oncol. 2023 Sep;28(9):1200-1206. doi: 10.1007/s10147-023-02383-1. Epub 2023 Jul 11. Int J Clin Oncol. 2023. PMID: 37432614
Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis.
Shimomura T, Mori K, Yasue K, Matsukawa A, Fukuokaya W, Yanagisawa T, Hata K, Murakami M, Koike Y, Miki J, Yamada H, Kimura T. Shimomura T, et al. Among authors: yasue k. Int J Clin Oncol. 2024 Feb;29(2):213-221. doi: 10.1007/s10147-023-02441-8. Epub 2023 Dec 16. Int J Clin Oncol. 2024. PMID: 38103156
Prognostic impact of histological discordance between transurethral resection and radical cystectomy.
Matsuda A, Taoka R, Miki J, Saito R, Fukuokaya W, Hatakeyama S, Kawahara T, Fujii Y, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Iio H, Yasue K, Abe T, Nakanishi S, Matsumura M, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Matsui Y; Japanese Urological Oncology Group. Matsuda A, et al. Among authors: yasue k. BJU Int. 2024 Feb 12. doi: 10.1111/bju.16296. Online ahead of print. BJU Int. 2024. PMID: 38344879
[The Effect of Local Therapy on Brain Metastasis of Renal Cell Carcinoma].
Yamazaki T, Kimura T, Kayano S, Kurauchi T, Ito K, Yasue K, Onuma H, Yanagisawa T, Murakami M, Yamada H, Egawa S. Yamazaki T, et al. Among authors: yasue k. Hinyokika Kiyo. 2021 Dec;67(12):521-524. doi: 10.14989/ActaUrolJap_67_12_521. Hinyokika Kiyo. 2021. PMID: 34991291 Free article. Japanese.
55 results